Screening for Human Immunodeficiency Virus and Other Sexually Transmitted Diseases Among U.S. Women With Prenatal Care

Abstract

III.

Coverage and outcomes of antenatal tests for infections: a population based survey in the Province of Trento, Italy

“…Testing coverage was over 95% in 12 out of the 18 European countries for HIV, in eight out of the 13 countries for HBV, in 14 out of the 18 countries for syphilis and in four countries out of the five countries for rubella [2]. In an analysis of a large administrative database in USA including 98,709 Medicaid-insured pregnant women, 96.3% were screened for syphilis, 96.3% for HBV, 82.4% for HIV [3].…”

Screening for Syphilis and Other Sexually Transmitted Infections in Pregnant Women — Guam, 2014

“…HIV screening was more common among women with Medicaid payment, blacks, and women aged <20 years. Another study, using 2009–2010 administrative claims data for women who received prenatal care in multiple U.S. states, reported high prenatal screening for syphilis (96.3%–97.8%) and lower screening for HIV infection (82.4%–85.4%), chlamydia (70.3%–83.1%), and gonorrhea (68.6%–74.8%); however, prenatal screening for specific STIs was similar among Medicaid and commercially insured women ( 8 ). This finding was in contrast to the data from Guam which indicated that more women covered by Medicaid or MIP had late or no syphilis screening (28.7%–48.4%) compared with privately insured women (13.1%).…”

HIV Status and Other Risk Factors for Prevalent and Incident Sexually Transmitted Infection during Pregnancy (2000-2014)

“…Although more than 285,000 women are living with HIV in the United States, current prenatal STI screening guidelines do not incorporate HIV status [36]. Compliance with these guidelines among commercially insured pregnant women in the United States averages 85-98% for syphilis and 69-83% for chlamydia and gonorrhea; rates that are comparable to the 83% testing rate in the current study [37]. More attention is needed to ensure high rates of screening at the initial visit and repeat testing among women at risk.…”